OncoCyte Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte or view top-rated stocks.

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

OncoCyte Co. (NYSEAMERICAN:OCX) posted its quarterly earnings data on Sunday, May, 16th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.05. OncoCyte had a negative net margin of 1,123.40% and a negative trailing twelve-month return on equity of 46.76%.
View OncoCyte's earnings history.

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OCX shares have increased by 145.3% and is now trading at $5.25.
View which stocks have been most impacted by COVID-19.

7 analysts have issued 12-month price objectives for OncoCyte's shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate OncoCyte's share price to reach $6.17 in the next twelve months. This suggests a possible upside of 17.5% from the stock's current price.
View analysts' price targets for OncoCyte or view top-rated stocks among Wall Street analysts.

Some companies that are related to OncoCyte include Lantheus (LNTH), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Aspira Women's Health (AWH), Quotient (QTNT), Lucira Health (LHDX), MyMD Pharmaceuticals (MYMD), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), ImmuCell (ICCC), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), ARCA biopharma (ABIO), Achieve Life Sciences (ACHV) and Biomerica (BMRA).
View all of OCX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), Brooklyn ImmunoTherapeutics (BTX), Fulcrum Therapeutics (FULC), Alnylam Pharmaceuticals (ALNY), VIVUS (VVUS), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX) and Aldeyra Therapeutics (ALDX).

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte's stock is owned by a number of retail and institutional investors. Top institutional investors include Pura Vida Investments LLC (13.75%), BlackRock Inc. (5.59%), Orbimed Advisors LLC (2.36%), Schonfeld Strategic Advisors LLC (1.83%), Geode Capital Management LLC (1.28%) and Nuveen Asset Management LLC (1.10%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including Penbrook Management LLC, GSA Capital Partners LLP, Morgan Stanley, BNP Paribas Arbitrage SA, and The Manufacturers Life Insurance Company.
View insider buying and selling activity for OncoCyte or view top insider-selling stocks.

OCX stock was acquired by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Orbimed Advisors LLC, Schonfeld Strategic Advisors LLC, BlackRock Inc., GW&K Investment Management LLC, AWM Investment Company Inc., Nuveen Asset Management LLC, and Parian Global Management LP. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte or or view top insider-buying stocks.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCX stock can currently be purchased for approximately $5.25.

OncoCyte has a market capitalization of $471.59 million and generates $1.22 million in revenue each year. The biotechnology company earns $-29,930,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

OncoCyte employs 51 workers across the globe.

The official website for OncoCyte is www.oncocyte.com.

OncoCyte is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515 or via email at [email protected]